Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Effects of carvedilol on structural and functional outcomes and plasma biomarkers in the mouse transverse aortic constriction heart failure model.

Hampton C, Rosa R, Szeto D, Forrest G, Campbell B, Kennan R, Wang S, Huang CH, Gichuru L, Ping X, Shen X, Small K, Madwed J, Lynch JJ.

SAGE Open Med. 2017 Mar 30;5:2050312117700057. doi: 10.1177/2050312117700057. eCollection 2017.

2.

Pharmacological Characterization of a Novel Beta 3 Adrenergic Agonist, Vibegron: Evaluation of Antimuscarinic Receptor Selectivity for Combination Therapy for Overactive Bladder.

Di Salvo J, Nagabukuro H, Wickham LA, Abbadie C, DeMartino JA, Fitzmaurice A, Gichuru L, Kulick A, Donnelly MJ, Jochnowitz N, Hurley AL, Pereira A, Sanfiz A, Veronin G, Villa K, Woods J, Zamlynny B, Zycband E, Salituro GM, Frenkl T, Weber AE, Edmondson SD, Struthers M.

J Pharmacol Exp Ther. 2017 Feb;360(2):346-355. doi: 10.1124/jpet.116.237313. Epub 2016 Dec 13.

PMID:
27965369
3.

Early echocardiographic predictors of outcomes in the mouse transverse aortic constriction heart failure model.

Hampton C, Rosa R, Campbell B, Kennan R, Gichuru L, Ping X, Shen X, Small K, Madwed J, Lynch JJ.

J Pharmacol Toxicol Methods. 2017 Mar - Apr;84:93-101. doi: 10.1016/j.vascn.2016.12.001. Epub 2016 Dec 9.

PMID:
27956205
4.

Discovery of Vibegron: A Potent and Selective β3 Adrenergic Receptor Agonist for the Treatment of Overactive Bladder.

Edmondson SD, Zhu C, Kar NF, Di Salvo J, Nagabukuro H, Sacre-Salem B, Dingley K, Berger R, Goble SD, Morriello G, Harper B, Moyes CR, Shen DM, Wang L, Ball R, Fitzmaurice A, Frenkl T, Gichuru LN, Ha S, Hurley AL, Jochnowitz N, Levorse D, Mistry S, Miller RR, Ormes J, Salituro GM, Sanfiz A, Stevenson AS, Villa K, Zamlynny B, Green S, Struthers M, Weber AE.

J Med Chem. 2016 Jan 28;59(2):609-23. doi: 10.1021/acs.jmedchem.5b01372. Epub 2016 Jan 8.

PMID:
26709102
5.

Design, synthesis, and evaluation of conformationally restricted acetanilides as potent and selective β3 adrenergic receptor agonists for the treatment of overactive bladder.

Moyes CR, Berger R, Goble SD, Harper B, Shen DM, Wang L, Bansal A, Brown PN, Chen AS, Dingley KH, Di Salvo J, Fitzmaurice A, Gichuru LN, Hurley AL, Jochnowitz N, Miller RR, Mistry S, Nagabukuro H, Salituro GM, Sanfiz A, Stevenson AS, Villa K, Zamlynny B, Struthers M, Weber AE, Edmondson SD.

J Med Chem. 2014 Feb 27;57(4):1437-53. doi: 10.1021/jm4017224. Epub 2014 Feb 5.

PMID:
24437735
6.

Transurethral bladder catheterization of male rhesus macaques: a refinement of approach.

Wickham LA, Kulick AA, Gichuru L, Donnelly MJ, Gai CL, Johnson CV, Hickey EJ, Nagabukuro H.

J Med Primatol. 2011 Oct;40(5):342-50. doi: 10.1111/j.1600-0684.2011.00494.x.

PMID:
21950722
7.

Comparative analysis of the effects of antimuscarinic agents on bladder functions in both nonhuman primates and rodents.

Nagabukuro H, Villa KL, Wickham LA, Kulick AA, Gichuru L, Donnelly MJ, Voronin GO, Pereira T, Tong X, Nichols A, Alves SE, O'Neill GP, Johnson CV, Hickey EJ.

J Pharmacol Exp Ther. 2011 Jul;338(1):220-7. doi: 10.1124/jpet.111.179747. Epub 2011 Apr 1.

PMID:
21459965
8.

Correlation between pharmacologically-induced changes in cystometric parameters and spinal c-Fos expression in rats.

Nagabukuro H, Degenhardt A, Villa KL, Mistry SL, Gichuru L, Jochnowitz N, Abbadie C.

Auton Neurosci. 2010 Aug 25;156(1-2):19-26. doi: 10.1016/j.autneu.2010.02.006. Epub 2010 Mar 24.

PMID:
20335078
9.
10.

Supplemental Content

Loading ...
Support Center